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Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease of spine and sacroiliac joints; it is
characterized by new bone formation, and the disease processes can be accompanied by osteoporosis. In the
present study, we investigated changes in bone mineral density (BMD) and in the levels of various bone
turnover-related biomarkers and cytokines in a cohort of AS patients, with regard to clinical parameters, disease
activity, and treatment regimen.
Methods: 55 AS patients and 33 healthy controls included in the study. Spinal mobility was assessed by the Bath
Ankylosing Spondylitis Metrology Index (BASMI), and radiologic changes were scored by the Bath Ankylosing
Spondylitis Radiologic Index (BASRI). Patients were also evaluated with the Bath Ankylosing Spondylitis Functional
Index (BASFI) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Bone mineral density (BMD)
assessed by dual energy X-ray absorptiometry. Various biomarkers and cytokines of bone turnover including
osteoprotegerin (OPG), serum band 5 tartrate-resistant acid phosphatase (TRAP-5), soluble receptor activator of
nuclear factor kappa-B ligand (sRANKL), secreted frizzled-related protein 1 (sFRP-1), Dickkopf-related protein 1
(DKK-1), and sclerostin were studied.
Results: The levels of TRAP-5, NTX, sRANKL, sclerostin, sFRP-1, DKK-1, and IFNγ, were similar between the patients
and controls (p> 0.05), while BMD of femoral neck, and OPG levels were significantly lower in AS patients (p< 0.05).
In a subgroup analysis, patients with active disease had significantly higher concentrations of OPG compared with
the inactive group. Rest of the biomarkers and cytokines of bone turnover were similar between the active and
inactive disease groups. Subgroup analysis of patients receiving anti-TNFα agents and conventional therapy
revealed that OPG concentrations were significantly lower in the patients receiving biological drugs, while BAP and
DKK-1 were significantly higher in the patients treated with conventional agents.
Conclusions: In this cross-sectional study we showed that OPG levels were significantly lower in AS patients
compared to healthy subjects. On the other hand, the levels of wingless (Wnt) signal pathway inhibitors seem not
altered. Ectopic bone formation in AS may be related to dysfunction of these molecules at the cellular level.
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Ankylosing spondylitis (AS), a chronic inflammatory dis-
ease of the spine and sacroiliac joints, is characterized by
new bone formation and is thereby associated with syn-
desmophytes and ankylosis [1]. Osteoporosis is also
present in AS and has multiple etiologies [2,3]. Several
biomarkers are known to be related to bone turnover. In
general, activation of osteoclasts (OCs) plays an import-
ant role in bone loss and the development of erosions.
Human receptor activator of nuclear factor-κβ ligand
(RANKL), a member of the tumor necrosis factor super
family, is one molecule that stimulates OCs. In contrast,
inhibition of OCs and activation of osteoblasts (OBs) are
linked with new bone formation and ossification. Osteo-
protegerin (OPG), which is produced by OBs, inhibits
RANKL and plays an important role in bone formation
[4]. Recently, various components of the Wnt pathway
signaling cascade were found to be involved in maintain-
ing bone mass. The most-studied secreted Wnt inhibi-
tors are sclerostin, dickkopfs (Dkks), and secreted
frizzled related proteins (sFRP1), which likely play im-
portant roles in bone turnover [5].
Various studies have aimed to identify and clarify the
mechanisms of bone turnover in AS, which results in
new bone formation and, paradoxically, osteoporosis [6-
13]. The use of anti-TNF treatments has provided new
insights into the treatment of inflammatory rheumatic
diseases, particularly AS and rheumatoid arthritis (RA).
Current data suggested that formation of syndesmo-
phytes is not prevented by anti-TNF treatments, despite
significant clinical improvement [14]. It is not known
why bone formation continues even when inflammation
is suppressed [14,15]; therefore; further studies are
needed to identify pathophysiological mechanisms re-
sponsible for new bone formation and osteoporosis in
AS. In the current study, we evaluated the biomarkers
and cytokines related to bone turnover in AS patients
who were treated with conventional agents and anti-
TNFs. We also investigated the relationship of bone
mineral density with various biomarkers of bone turn-
over and clinical parameters.
Methods
Fifty-five consecutive patients diagnosed with AS
according to modified New York criteria [16], and 33
age- and sex-matched healthy controls were enrolled in
this study. Subjects with a history of neuroendocrine dis-
order (thyroid, parathyroid disorder, and anticonvulsant
usage), chronic renal and liver disease, systemic steroid
usage, menopause, cigarette smoking, or excessive alco-
hol usage were excluded from the study.
Patients provided informed written consent to partici-
pate, and the study protocol was approved by the ethical
committee of the Tepecik Hospital. Spinal mobility wasassessed by the Bath Ankylosing Spondylitis Metrology
Index (BASMI) [17]. Radiologic changes were scored
by the Bath Ankylosing Spondylitis Radiologic Index
(BASRI) [18]. Patients were also evaluated with the Bath
Ankylosing Spondylitis Functional Index (BASFI) [19] and
the Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) [20]. Patients with a BASDAI≥ 4 were defined
as having active disease. Conventional treatment included
non-steroidal anti-inflammatory drugs (NSAIDs) and/or
sulfasalazine, but not anti-TNF-α drugs.
Laboratory evaluation
Following an overnight fast, venous blood samples for la-
boratory tests were collected between 8:00 and 9:00 AM.
Serum samples were preserved at −80°C until assayed. The
following ELISA kits were used according to the manufac-
turer’s instructions: Serum high sensitive C- reactive pro-
tein (hs-CRP, Cat. No.: EIA-3954, DRG International,
USA), interleukin 6 (IL-6, Cat. No.: EK0410, Boster Bio-
logical Technology Co., Ltd., China), vitamin D (Cat. No.: K
2110 ko, ImmunDiagnostik, Bensheim, Germany), bone-
specific alkaline phosphatase (BAP, QUIDEL, San Diego,
CA, USA), cross-linked N-telopeptide of type I collagen
(NTx, OsteomarkW NTx serum, Princeton, NJ, USA),
serum band 5 tartrate-resistant acid phosphatase (TRAP-5,
Cat. No.: RD197025000, Biovendor Laboratory Medicine,
Brno, Czech Republic), soluble receptor activator of nuclear
factor kappa-B ligand (sRANKL, Cat. No.: RD193004200R,
Biovendor Laboratory Medicine, Brno, Czech Republic),
osteoprotegerin (OPG, Cat. No.: EK0480, Boster Biological
Technology Co., Ltd., China), sclerostin (Cat. No.: BI-
20492, Biomedica Gruppe, Vienna, Austria), Dickkopf-
related protein 1 (DKK-1, Cat. No.: BI-20412, Biomedica
Gruppe, Vienna, Austria), secreted frizzled-related protein
1 (sFRP-1, Cat. No.: E95880Hu, USCN, Wuhan, China),
human parathyroid hormone (hPTH, Cat. No.: KAP1481,
The DIAsource hPTH-EASIA, Niveles, Belgium) serum
interferon-gamma (IFN-γ, Cat. No.: EI1023-1, AssayPro, St.
Charles, MO, USA).
Bone densitometry assessment
Axial and appendicular BMD of lumbar spine (L2-L4,
posteroanterior view) and the left proximal femur (neck,
intertrochanteric area, greater trochanter, and ward’s tri-
angle) were assessed using the AP dual-energy x-ray ab-
sorptiometry DEXA (Hologic QDR 1000, Waltham, MA,
USA). The results were expressed as g/cm2.
Statistical analysis
The Kolmogorov-Smirnov normality test was used to de-
termine the distribution pattern of the variables. The
majority of the parameters including ESR, BAP, DKK-1,
hPTH, IL-6, sFRP1, IFN-γ, and sRANKL/OPG ratio
showed non-normal distribution, and we used non-
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Whitney U-test was used for comparisons between two
groups of continuous variables. Fisher's exact test was
performed for the comparison of categorical variables.
The Spearman’s rho correlation was used to determine
relationships between parameters. Results were pre-
sented as median with minimum–maximum (range)
values. Statistical analysis was carried out using the
Statistical Package for the Social Science, version 13.0
(Chicago, IL, USA). A two-tailed p value of <0.05 was
considered significant.
Results
Of the 55 AS patients, 48 were male, 7 were female, and
the median age was 36 years (range, 19–61); of the 33
healthy controls, 24 were male, 9 were female, and the
median age was 39 years (range, 23–48). In the patient
group, the median disease duration was 10 (2–40) years.
BASDAI, BASFI, BASMI, BASRI hip, and BASRI spine
indices were 5 (1–9), 3.7 (0.1–8.8), 3 (1–9), 0 (0–4), and
6 (2–12), respectively. HLAB-27 positivity was 64.9%.
None of the individuals had any personal or family his-
tory of psoriasis or inflammatory bowel disease. Only
one patient had a history of hip prosthesis.
Age and sex distributions were similar between
patients and controls (p=non-significant [NS]). Anthro-
pometrical parameters, including body mass index
(BMI) and waist circumference, were also comparable
between the groups (p=NS). Biochemical examination
showed that serum levels of calcium, phosphor, BAP,
and vitamin D did not differ between patients and con-
trols (p=NS). However, acute phase proteins, including
ESR, hs-CRP, and IL-6, were significantly higher in the
AS group (p < 0.05). Bone turnover parameters, includ-
ing TRAP 5, NTX, sRANKL, sclerostin, sFRP-1, DKK-1,
and IFNγ, were similar between the groups (p=NS). On
the other hand, hPTH and OPG levels were significantly
lower in the AS group [p < 0.05; 46 (44–170) vs. 78 (45–
180) pg/mL and 339 (52–1118) vs. 527 (16–1030) pg/
mL, respectively]. BMD of femoral neck in the patient
group was significantly lower than in the controls
[p < 0.05; 0.8 (0.5–1) vs. 0.9 (0.6–1.1) g/cm2]. However,
BMD lumbar spine did not differ between the groups
(p=NS). The clinical and laboratory characteristics of
AS patients and controls are given in Table 1.
Comparison of AS subjects receiving anti-TNF agents and
conventional therapy
Thirty-two patients were treated with conventional
drugs (NSAIDS and/or sulfasalazine), and 23 were trea-
ted with anti-TNFα drugs (9 infliximab, 8 etanercept,
and 6 adalimumab). Age distribution was similar be-
tween the groups (p=NS). The median treatment dur-
ation of biologics was 24 (16–33) months. All subjectstreated with TNFα-targeting agents received their treat-
ments regularly, and none of the patients treated with
conventional drugs had received anti-TNFα agents in
their past medical history. Comparison of the patients
on anti-TNFα and conventional drug therapies revealed
that all biochemical parameters were similar in both
treatment groups (p=NS), except for BAP, DKK-1, and
OPG. BAP and DKK-1 concentrations were significantly
higher in the patients receiving anti-TNFα drugs
[p < 0.05; 33 (17–107) vs. 28 (13–47) U/L, and 108 (39–
771) vs. 87 (17–370), pg/mL respectively], while OPG
levels were lower [p < 0.05; 274 (52–1080) vs. 384 (84–
1118) pg/mL respectively] in the anti-TNFα treatment
group compared to conventional therapy. BASRI-hip
and -spine indices and BMD assessments (lumbar and
femoral neck) did not differ between the treatment
groups (p=NS). Table 2 summarizes the parameters of
the two treatment groups.
Comparison of AS subjects with respect to disease
activity
Thirty-eight AS patients had active disease (BASDAI≥
4), and 17 cases were inactive. Age and sex distributions
were similar between patients with active and inactive
disease (p=NS). Studied bone turnover markers, except
OPG, were comparable between active and inactive dis-
ease states (p=NS). OPG concentrations were signifi-
cantly higher in the active AS group compared to the
inactive patients [p < 0.05; 367 (52–1118) vs. 274 (71–
592) pg/mL). BASRI-hip and -spine indices and BMD
assessments (lumbar and femoral neck) were also not
different between active and inactive patients (p=NS).
Data from patients with active and inactive diseases are
shown in Table 3.
Correlation analysis
Upon correlation analysis, sclerostin was found to be
correlated with disease duration, lumbar BMD, DKK-1,
and PTH (p < 0.05; r = 0.3, 0.2, 0.2, and 0.3, respectively).
DKK-1 showed correlations with BASMI, sclerostin, and
SFRP-1 (p < 0.05; r = 0.3, 0.2, and −0.2, respectively).
sRANKL was correlated with disease duration, BASRI-
spine, and BASMI (p < 0.05; r =−0.3, −0.4, and −0.4 re-
spectively). Lumbar BMD was correlated with disease
duration, BASRI-spine, femoral neck BMD, BASMI, and
sclerostin (p < 0.05; r = 0.3, 0.3, 0.3, 0.4, and 0.2 respect-
ively). OPG showed correlations with BASDAI≥ 4
(p < 0.05; r = 0.3). Other significant correlations were
summarized in Table 4.
Discussion
The present study showed that AS patients had lower
serum OPG levels and a higher RANKL/OPG ratio com-
pared to healthy controls. Previous studies have shown
Table 1 Clinical and laboratory characteristics of AS patients and controls
AS Patients (n = 55) Controls (n = 33) p value
Age (years) 36 (19–61) 39 (23–48) 0.9
Sex (M/F) 48/7 24/9 0.1
BMI (kg/m2) 25 (18–37) 25 (20–31) 0.9
Waist circumference (cm) 92 (66–120) 89 (65–104) 0.2
BMD-Lumbar spine (g/cm2) 0.9 (0.7–1.6) 1 (0.8–1.2) 0.1
BMD-Femoral neck (g/cm2) 0.8 (0.5–1.1) 0.9 (0.6–1.1) 0.002
ESR (mm/h) 17 (3–72) 9 (1–30) <0.0001
hs-CRP (mg/L) 8.5 (0.6–24.3) 2.5 (0–9.9) <0.0001
IL-6 (pg/mL) 18.5 (5–545) 8.1 (4–69) <0.0001
IFNγ (pg/mL) 0.002 (0.002–1.956) 0.002 (0.002–0.313) 0.5
BAP (U/L) 29 (13–107) 26 (2–51) 0.1
Calcium (mg/L) 10 (9–11) 9.9 (9.3–11) 0.7
Phosphor (mg/dL) 1.3 (1.7–4.7) 3.4 (2.2–4,5) 0.9
Vitamin D (nM) 87 (4–266) 102 (10–303) 0.5
NTX (nM, bone collagen equivalent) 82 (52–188) 84 (57–106) 0.3
TRAP 5 (U/L) 3.8 (2.3–6.6) 3.7 (2.3–8.34) 0.3
hPTH (pg/mL) 46 (44–170) 78 (45–180) 0.02
sRANKL (pmol/L) 284 (101–1598) 292 (143–783) 0.8
OPG (pg/mL) 339 (52–1118) 527 (16–1030) 0.02
sRANKL/OPG 0.99 (0.14-22.6) 0.65 (0.14–25.1) 0.04
Sclerostin (pmol/L) 73 (48–126) 77 (49–110) 0.2
sFRP1 (ng/mL) 0.14 (0.1–16.7) 0.2 (0.1–1.2) 0.4
DKK1 (pg/mL) 97 (17–771) 115 (29–278) 0.7
Data are presented as the median with minimum and maximum values. ESR= erythrocyte sedimentation rate, hs-CRP= high sensitive C- reactive protein, IL-6=
interleukin 6, IFNγ= interferon-gamma, BAP= bone-specific alkaline phosphatase, NTX= cross-linked N-telopeptide of type I collagen, TRAP 5= serum band 5
tartrate-resistant acid phosphatase, hPTH= human parathyroid hormone, sRANKL= soluble receptor activator of nuclear factor kappa-B ligand, OPG=
osteoprotegerin, sFRP1= secreted frizzled-related protein 1, DKK1= Dickkopf-related protein 1.
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ies revealed elevated OPG levels in AS patients com-
pared to healthy controls [6,9,12]. However, a study in a
Korean cohort found no differences in serum levels of
OPG between AS patients and normal subjects [11]. In a
cohort of 240 AS patients, Franck et al. found that AS
patients generally had lower serum OPG level and
higher RANKL/OPG ratio; they also reported a lack of
compensatory increase of OPG with age in AS patients
[8]. Subgroup analysis of our results also revealed that
active disease state (BASDAI≥ 4) was associated with
higher OPG levels. This result is in agreement with the
findings of Chen et al., who found OPG to be correlated
with poor physical mobility and increased inflammatory
state in AS patients; however, in contrast to our results,
that study found RANKL and OPG to be elevated com-
pared to controls [6]. Osteoprotegerin inhibits osteoclas-
togenesis by binding RANKL, acting as a decoy receptor
to competitively inhibit RANKL interaction with its re-
ceptor RANK. Thus, decreased OPG levels in AS
patients might have contributed to the lowered BMDdetected at femur in our study group [4]. On the other
hand, hypothetically, the excess production of OPG dur-
ing active disease state could contribute to the new bone
formation. In this study, we also showed that, anti-TNF
treated AS patients had significantly lower levels of OPG
compared with the conventionally treated patients. This
observation is in line with a prospective study performed
by Kwon et al. who showed anti-TNF treatment had a
negative effect on OPG concentrations [12].
The discrepancies between the results of various stud-
ies may be due to the effects of various disease states and
treatment types on the RANKL/OPG axis, as well as the
complex interaction of various cytokines and signaling
molecules. In our study, RANKL was similar in AS
patients and healthy controls, was not altered with treat-
ment, and showed no relation with clinical parameters;
in contrast, Kim et al. found increased RANKL level cor-
relating with disease activity markers [11]. RANKL is an
important cytokine, but osteoclastogenesis is also influ-
enced by TNF, IL-1, IL-6, IL-17, vitamin D3, and prosta-
glandin E2 [21,22]. OPG balances bone resorption, and is
Table 2 Comparison of AS subjects with respect to treatment type
Anti-TNF treatment(n = 23) Conventional treatment(n = 32) p value
BASFI 3.7 (1.5–7.7) 3.8 (0.1–8.8) 0.4
BASDAI 4 (1.3–8.1) 5.5 (1–9) 0.08
BASRI-hip 0 (0–4) 0 (0–2.5) 0.1
BASRI-spine 7.5 (2–12) 5.5 (2–12) 0.09
BASMI 4 (1–9) 2 (1–9) 0.003
BMD-Lumbar spine (g/cm2) 1 (0.7–1.6) 0.9 (0.8–1.4) 0.3
BMD-Femoral neck (g/cm2) 0.8 (0.6–1) 0.8 (0.5–1.1) 0.5
IL-6 (pg/mL) 13 (5–545) 20 (6–300) 0.9
IFNγ (pg/ml) 0.002 (0.002–0.03) 0.002 (0.002–1.96) 0.6
BAP (U/L) 33 (17–107) 28 (13–47) 0.04
Vitamin D (nM) 84 (12–266) 92 (4–244) 0.9
NTX (nM, bone collagen equivalent) 78 (52–188) 83 (64–114) 0.4
TRAP 5 (U/L) 4 (2.3–5.8) 3.7 (2.3–6.6) 0.3
hPTH (pg/mL) 46 (44–130) 46 (44–170) 0.8
sRANKL (pmol/L) 284 (103–1598) 285 (101–956) 0.5
OPG (pg/mL) 274 (52–1080) 384 (84–1118) 0.04
sRANKL/OPG 1.28 (0.2–22.6) 0.73 (0.14–4.5) 0.03
Sclerostin (pmol/L) 75 (48–95) 68 (49–126) 0.6
sFRP1 (ng/mL) 0.1 (0.1–17) 0.2 (0.1–0.4) 0.1
DKK1 (pg/mL) 108 (39–771) 87 (17–370) 0.03
Data are presented as the median with minimum and maximum values. BASFI= Bath ankylosing apondylitis functional index, BASDAI= Bath ankylosing spondylitis
disease activity index, BASMI= Bath ankylosing spondylitis metrology index, BASRI= Bath Ankylosing spondylitis radiologic index, IL-6= interleukin 6, IFNγ=
interferon-gamma, BAP= bone-specific alkaline phosphatase, NTX= cross-linked N-telopeptide of type I collagen, TRAP 5= serum band 5 tartrate-resistant acid
phosphatase, hPTH= human parathyroid hormone, sRANKL= soluble receptor activator of nuclear factor kappa-B ligand, OPG= osteoprotegerin, sFRP1= secreted
frizzled-related protein 1, DKK1= Dickkopf-related protein 1.
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[23]; all of these cytokines are expressed differently in
cases of certain disease activity and treatment. Woo et al.
reported that etanercept therapy didn’t change RANKL/
OPG levels, but improved bone metabolic markers and
BMD in AS patients [24]. In our study, we observed that
sRANKL/OPG ratio was significantly higher in patients
treated with anti-TNF therapies. Although sRANKL did
not change between the treatments groups, this signifi-
cance was a consequence of lower OPG concentrations
in the biological treatment group. The effects of inflam-
mation on bone remodeling have different outcomes in
different rheumatic diseases, such as RA and AS [25]. In
both diseases, decreased bone mineral density is
expected, including juxta-articular osteopenia in RA and
decreased BMD mainly at vertebras and hip in AS [2,3].
In this study, BMD of femoral neck was significantly
decreased in AS patients, but BMD of lumbar spine did
not differ from the healthy controls. These observations
may be due to be the interference of syndesmophytes
and ectopic calcifications with BMD measurement at
lumbar spine. Low PTH and OPG in AS patients may be
explanatory to the finding of decreased BMD of femoral
neck as we noted previously.In our study, the serum levels of Wnt signaling pathway
inhibitors, DKK-1, Sclerostin, and sFRP1, were not differ-
ent in AS patients from the healthy controls. However,
subgroup analysis showed that patients receiving anti-
TNFα treatment had higher DKK-1 levels compared to
patients taking conventional drugs. Daoussis et al. recently
measured DKK-1 level using two different serum assays; a
sandwich Elisa assay that showed circulating DKK-1 indi-
cated that serum DKK-1 was increased in AS patients
compared to healthy controls, but a functional ELISA
model showed decreased binding of DKK-1 to the LRP-6
receptor [7]. Diarra et al. also found that, in contrast to
RA, DKK-1 levels in AS were very low and showed no re-
lation with measures of disease activity [26]. Lane et al.
found that higher DKK-1 levels were protective and
diminished the risk of radiologic progression for hip OA,
another disease associated with bone formation [27]. All
of these studies suggest that either dysfunction or
decreased level of DKK-1 is crucial for new bone forma-
tion in AS. In our study, increased DKK-1 level in AS
patients who were on anti-TNF treatment are noteworthy,
since the balance between DKK-1 and Wnt is important
for bone turnover. In Diarra et al.’s study, DKK-1 levels in
RA patients were diminished with anti-TNF drugs, but
Table 3 Comparison of AS subjects with respect to disease activity
Active patients (BASDAI ≥ 4; n = 38) Inactive patients (BASDAI < 4; n = 17) p value
IL-6 (pg/mL) 20 (6–545) 15 (5–277) 0.2
IFNγ (pg/mL) 0.002 (0.002–1.96) 0.002 (0.002–0.89) 0.7
BAP (U/L) 28 (13–107) 30 (15–49) 0.3
Vitamin D (nM) 89 (4–266) 77 (12–240) 0.6
NTX (nM, bone collagen equivalent) 87 (56–131) 81 (52–188) 0.7
TRAP 5 (U/L) 3.7 (2.2–5.8) 3.9 (2.4–6.6) 0.4
hPTH (pg/mL) 46 (44–170) 77 (45–130) 0.08
sRANKL (pmol/L) 264 (101–956) 350 (158–1598) 0.2
OPG (pg/mL) 367 (52–1118) 274 (71–592) 0.004
sRANKL/OPG 0.79 (0.14–4.5) 1.16 (0.4–22.6) 0.02
Sclerostin (pmol/L) 70 (49–126) 75 (48–123) 0.7
sFRP1 (ng/mL) 0.15 (0.1–17) 0.1 (0.1–0.2) 0.5
DKK1 (pg/mL) 93 (26–370) 130 (17–771) 0.5
BASRI-hip 0 (0–4) 0.5 (0–4) 0.2
BASRI-spine 5.5 (2–12) 7 (2–12) 0.3
BASMI 4 (1–9) 2.5 (1–9) 0.7
BMD-Lumbar spine (g/cm2) 0.9 (0.7–1.4) 0.9 (0.7–1.6) 0.8
BMD-Femoral neck (g/cm2) 0.7 (0.6–1.1) 0.8 (0.5–1) 0.9
Data are presented as the median with minimum and maximum values. BASDAI= Bath ankylosing spondylitis disease activity index, IL-6= interleukin 6, IFNγ= interferon-
gamma, BAP= bone-specific alkaline phosphatase, NTX= cross-linked N-telopeptide of type I collagen, TRAP 5= serum band 5 tartrate-resistant acid phosphatase,
hPTH= human parathyroid hormone, sRANKL= soluble receptor activator of nuclear factor kappa-B ligand, OPG= osteoprotegerin, sFRP1= secreted frizzled-related
protein 1, DKK1= Dickkopf-related protein 1, BASRI= Bath Ankylosing spondylitis radiologic index, BASMI= Bath ankylosing spondylitis metrology index.
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to our results, decreased OPG and increased DKK-1 in
patients on anti-TNF therapy suggest a trend favoring
osteoclastogenesis in these patients. However, prospective
studies are needed to determine the net effect of biological
therapies on bone metabolism.Table 4 Correlation coefficients of the some clinical and labo
Disease duration BASRI-h BASRI-s BMD-f BMD-l B
Disease duration 0.3 0.6 0.3
BASRI-h 0.3 0.6
BASRI-s 0.6 0.6 0.3
BMD-f 0.3
BMD-l 0.3 0.3 0.3
BASDAI ≥ 4 −0.3







Values indicate correlation coefficients. Note that empthy cells indicate no significa
radiology index hip, and spine respectively, BMD-f, and BMD-l= BMD femoral neck
index, BASDAI= Bath ankylosing spondylitis disease activity index, BASMI= Bath ank
nuclear factor kappa-B ligand, OPG= osteoprotegerin, sFRP1= secreted frizzled-relatConclusions
In this cross-sectional study we showed that OPG levels
were significantly down regulated in AS patients com-
pared to healthy subjects. Serum concentrations of OPG
tend to be higher in patients with active disease state
suggesting a trend favoring osteoblastic activity in theseratory data












nce between variables. BASRI-h, and BASRI-s= Bath ankylosing spondylitis
and lumbar spine respectively, BASFI= Bath ankylosing apondylitis functional
ylosing spondylitis metrology index, sRANKL= soluble receptor activator of
ed protein 1, DKK1= Dickkopf-related protein 1.
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http://www.biomedcentral.com/1471-2474/13/191patients. The levels of Wnt signal pathway inhibitors
seem not altered in AS. Ongoing ectopic bone forma-
tion, one of the one of the hallmark features of AS, may
be related to dysfunction of these molecules at the cellu-
lar level.
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